ipsen biopharmaceuticals canada

What ipsen biopharmaceuticals canada does

Ipsen Biopharmaceuticals Canada Inc. is the Canadian operating subsidiary of global biopharmaceutical company Ipsen S.A., incorporated in Ontario and doing business as Ipsen. The company markets and distributes Dysport Therapeutic, a prescription botulinum toxin type A product, for approved therapeutic indications including cervical dystonia and other movement disorders in the Canadian market. Its core product is delivered through a dedicated bilingual (English/French) portal at dysporttherapeutic.ca, which provides separate authenticated access for healthcare professionals and patients.

The underlying technology is the Dysport Therapeutic formulation itself, a proprietary botulinum toxin type A developed and trademarked by the Ipsen group (Dysport Therapeutic is a registered trademark of Ipsen Biopharm Ltd.; Ipsen is a registered trademark of Ipsen S.A.). The digital surface supporting the product consists of a healthcare-professional portal secured by IQVIA's OneKey Web Authentication service and a patient login gated by an eight-digit Drug Identification Number (DIN). The Dysport Advantage Program, a registered patient support program, provides wraparound services to patients prescribed the product. The website carries Pharmaceutical Advertising Advisory Board (PAAB) verification and the company holds membership in Innovative Medicines Canada.

The business model is prescription pharmaceutical sales: revenue is generated when Canadian physicians (primarily neurologists and movement disorder specialists) prescribe Dysport Therapeutic, which is then dispensed through pharmacies to patients, with payment flowing through provincial drug formularies and private insurance plans. Pricing is not publicly disclosed. The company serves two primary customer segments: healthcare professionals (who prescribe the product and access clinical information through the authenticated portal) and patients (who access the product via prescription and use the support program). As a privately held subsidiary of a strategic parent, the entity reports no independent revenue, headcount, funding, or M&A activity in the provided materials.

Name

ipsen biopharmaceuticals canada

Legal name

Ipsen Biopharmaceuticals Canada Inc.

Website

https://dysporttherapeutic.ca

Company type

Private

Operating status

Operating

Short description

Ipsen Biopharmaceuticals Canada Inc. is the Canadian subsidiary of global biopharmaceutical Ipsen S.A., marketing the prescription botulinum toxin type A product Dysport Therapeutic to Canadian healthcare professionals and patients through a dedicated online portal and patient support program.

Ownership category

akta.pro rank

Product category

Prescription Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Prescription pharmaceuticals
• Botulinum toxin therapy
• Neurology therapeutics
• Patient support programs
• Biopharmaceutical distribution

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Prescription Pharmaceutical Sales: Ipsen Biopharmaceuticals Canada generates revenue through the sale of prescription therapeutic products, specifically Dysport Therapeutic (a botulinum toxin type A product). The product is prescribed by healthcare professionals and dispensed through pharmacies to patients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Ipsen Biopharmaceuticals Canada Inc. markets and distributes Dysport Therapeutic, a prescription botulinum toxin type A product, in the Canadian market. The company operates a dedicated website portal with separate, authenticated access for healthcare professionals (via IQVIA OneKey Web Authentication) and for patients (via Drug Identification Number verification), and runs the Dysport Advantage Program patient support offering.

Product overview

Ipsen Biopharmaceuticals Canada operates as a single-product pharmaceutical company, offering Dysport Therapeutic as its core branded medication. The company website serves as an informational and authentication portal, providing separate access points for healthcare professionals (via IQVIA OneKey Web Authentication) and patients (via DIN-based verification), rather than a multi-module software platform.

Differentiator

Problem solved

Functional benefit

Brands

• Dysport Therapeutic: A therapeutic botulinum toxin product for medical use in Canada

Products and services

• Dysport Therapeutic Dysport Therapeutic is a prescription botulinum toxin type A medication for approved therapeutic indications (including cervical dystonia and other movement disorders), prescribed by Canadian healthcare professionals and dispensed through pharmacies to patients. The product is supported by a dedicated HCP/patient portal and the Dysport Advantage Program.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core and minor.

• IQVIAcoreTechnology or IntegrationIQVIA provides OneKey Web Authentication (OWA) service to validate healthcare professional login on the Dysport Therapeutic portal. This is a third-party authentication service managed by IQVIA for Ipsen.
• Health CanadacoreOthersRegulatory relationship for adverse reaction reporting. Healthcare professionals and patients can report suspected side effects to Health Canada's Canada Vigilance Program via their website or toll-free line 1-866-234-2345.
• Innovative Medicines CanadacoreOthersIpsen Biopharmaceuticals Canada is a member of Innovative Medicines Canada, the industry association representing Canada's innovative pharmaceutical companies.
• Pharmaceutical Advertising Advisory Board (PAAB)minorOthersThe Dysport Therapeutic website bears the PAAB verified logo, indicating compliance with pharmaceutical advertising standards in Canada.

Recent moves6 records

Expansion highlights2 records

Direct peers

• AbbVie (Allergan Aesthetics): Markets Botox® (onabotulinumtoxinA), the dominant therapeutic and aesthetic botulinum toxin brand. Directly competes with Ipsen's Dysport for HCP prescriptions and formulary listing in Canada across movement disorder and other therapeutic indications.
• Merz Pharmaceuticals: Markets Xeomin® (incobotulinumtoxinA), a competing therapeutic botulinum toxin. Targets the same neurology and movement disorder specialist prescriber base as Dysport Therapeutic in Canada.

Broad incumbents

• Ipsen S.A. Global biopharmaceutical company and parent of Ipsen Biopharmaceuticals Canada Inc. Owns the Dysport franchise globally; the Canadian entity is a national subsidiary of this broader innovative medicines company.
• Galderma: Global dermatology-focused company with aesthetic neuromodulator offerings (originally Dysport's aesthetic counterpart via partnership history). Adjacent competitor in the broader botulinum toxin category, primarily in aesthetics.

Emerging players

• Revance Therapeutics: Develops next-generation neuromodulators (e.g., Daxxify®) with longer-duration claims. Represents an emerging therapeutic botulinum toxin competitor that could pressure Dysport's positioning in Canadian specialty channels.
• Hugel (Letybo/Botulax): South Korean biopharmaceutical company marketing botulinum toxin products (Letybo, Botulax) internationally. An emerging global competitor that could expand into Canada and pressure Dysport on price.

Others

• Supernus Pharmaceuticals: Specialty CNS therapeutics company with neurology-focused commercial infrastructure in North America. Adjacent competitor operating in similar movement disorder and specialty neurology channels, though without a directly competing neuromodulator.

Regional players

• Bausch Health Canada: Canadian pharmaceutical subsidiary of Bausch Health operating across multiple therapeutic areas. Comparable as a regional pharma distribution entity with HCP-facing infrastructure in Canada, though without a directly competing botulinum toxin product.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ipsen biopharmaceuticals canada